Daina Graybosch
Stock Analyst at Leerink Partners
(1.31)
# 3,643
Out of 5,090 analysts
98
Total ratings
42.65%
Success rate
-7.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $0.53 | +280.52% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.89 | +5.82% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.73 | +173.90% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.99 | +251.76% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $18.31 | -34.46% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $99.72 | +19.33% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.42 | +269.00% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $69.56 | -43.93% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $56.90 | -20.91% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.08 | +825.93% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $25.45 | +49.31% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.52 | +76.99% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $96.25 | +132.73% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.80 | +1,566.67% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.95 | +1,686.28% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.51 | +496.03% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $0.53
Upside: +280.52%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.89
Upside: +5.82%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.73
Upside: +173.90%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.99
Upside: +251.76%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $18.31
Upside: -34.46%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $99.72
Upside: +19.33%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.42
Upside: +269.00%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $69.56
Upside: -43.93%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $56.90
Upside: -20.91%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.08
Upside: +825.93%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $25.45
Upside: +49.31%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.52
Upside: +76.99%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $96.25
Upside: +132.73%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.80
Upside: +1,566.67%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.95
Upside: +1,686.28%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.51
Upside: +496.03%